Grifols Procleix ArboPlex Assay Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening - Seite 2
The Procleix ArboPlex Assay will be available in all markets accepting the CE mark certification after completion of any additional registration and notification requirements.
About Procleix ArboPlex Assay
The Procleix ArboPlex Assay is a nucleic acid test (NAT) that uses magnetic-based target capture,
Transcription-Mediated Amplification (TMA) and chemiluminescence to detect the presence of RNA sequences of four arboviruses (chikungunya virus, dengue virus RNA, West Nile virus RNA, and Zika
virus) in plasma and serum from human donors. The high sensitivity and specificity of the Procleix technology enables pathogen detection to reduce the risk of transfusing infected blood or blood
components, even when the donor does not exhibit symptoms. The assay runs on the widely adopted Procleix Panther System, an automated NAT instrument from Grifols.
About Procleix Panther System
The Procleix Panther System automates all aspects of NAT-based blood screening on a single, integrated platform, and is capable of delivering the
highest result throughput per square meter. It eliminates the need for batch processing and combines walk-away freedom with intuitive design for ease of use. For more information, please visit
www.diagnostic.grifols.com.
About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in
essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.
Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East and China.
As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.